检索结果-南通市图书馆

The ACTIVE study protocol:apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer(CTONG1706)

在线全文

学校读者我要写书评

暂无评论

Cancer Communications 2019年第1期39卷 607-614页

作者： Zhonghan Zhang Fan Luo Yang Zhang Yuxiang Ma shaodong hong Yunpeng Yang Wenfeng Fang Yan Huang Li Zhang hongyun Zhao State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer MedicineGuangzhou 510060GuangdongP.R.China Department of Medical Oncology Sun Yat-sen University Cancer Center651 Dongfeng Road EastGuangzhou 510060GuangdongP.R.China Department of Clinical Research Sun Yat-sen University Cancer Center651 Dongfeng Road EastGuangzhou 510060GuangdongP.R.China

Background:Gefitinib,as the first epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKI)approved for the treatment of advanced non-small cell lung cancer(NSCLC),has been proved to significantly improve the progression-free survival(PFS)in the first-line setting but suffers from resistance 7-10 months after treatment ***(YN968D1),a potent vascular endothelial growth factor receptor(VEGFR)2-TKI,specifically binds to VEGFR2 and leads to anti-angiogenetic and anti-neoplastic *** inhibition of VEGFR and EGFR path-ways represents a rational approach to improve treatment responses and delay the onset of treatment resistance in EGFR-mutant *** ACTIVE study aims to assess the combination of apatinib and gefitinib as a new treatment approach for EGFR-mutant NSCLC as a first-line ***:This multicenter,randomized,double-blind,placebo-controlled phase III study(NCT02824458)has been designed to assess the efficacy and safety of apatinib or placebo combined with gefitinib as a first-line treatment for patients with EGFR-mutant advanced NSCLC.A total of 310 patients with EGFR-mutation(19del or 21L858R),pathological stage IIIB to IV non-squamous NSCLC were to be *** primary endpoint is investigator assessment of PFS,and the secondary endpoints include independent radiological central(IRC)-confirmed PFS,overall survival(OS),objective response rate(ORR),disease control rate(DCR),time to progressive disease(TTPD),duration of response(DoR),quality of life(QoL)and *** patients are randomized in a 1:1 ratio to receive gefitinib(250 mg,p.o.q.d.)plus apatinib(500 mg,p.o.q.d.)or gefitinib plus placebo,given until disease progression or intolerable adverse *** biomarker analysis will be *** study is being conducted across China and comprises of 30 participating *** commenced in August 2017 and finished in December 2018,most of the patients are in the follow-up ***

关键词： NSCLC EGFR VEGFR Tyrosine kinase inhibitors Apatinib Gefitinib Randomized Double-blind Placebo Phase III

A multicenter,*** survey of the clinical features and management of bone metastatic disease in China

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Journal of Cancer 2016年第5期35卷 223-228页

作者： Yunpeng Yang Yuxiang Ma Jin Sheng Yan Huang Yuanyuan Zhao Wenfeng Fang shaodong hong Ying Tian Cong Xue Li Zhang Department of Medical Oncology Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer Medicine

Background:Bone metastases are common in patients with advanced ***(BPs) could prevent or delay the development of skeleton-related events(SREs).The present study aimed to identify the clinical features of and treatment strategies for Chinese patients with bone ***:Consecutive cancer patients who had bone metastases and received BP treatment were enrolled.A questionnaire was developed to collect the patients' clinical data,as well as information on the diagnosis and management of bone ***' awareness of the guidelines and knowledge of the application of BP were also ***:A total of 3223 patients with lung cancer(36.5%),breast cancer(30.9%),prostate cancer(8.5%),and gastrointestinal cancer(5.7%) were included in this *** sites of bone metastases were the thoracic spine(56.0%),lumbar spine(47.1%),ribs(32.6%),and pelvis(23.2%).The SRE frequency was the highest in patients with multiple myeloma(36.6%),followed by those with lung cancer(25.9%),breast cancer(20.2%),prostate cancer(18.2%),and gastrointestinal cancer(17.3%).Irradiation to the bone was the most frequent SRE(58%in lung cancer patients,45%in breast cancer patients,and 48%in prostate cancer patients).Our survey also showed that 45.5%of patients received BP within 3 months after their diagnosis of bone metastases,whereas the remaining 54.5%of patients did not receive BP treatment until at least 3 months after their diagnosis of bone *** SRE frequency in the former group was significantly lower than that in the latter group(4.0%vs.42.3%,P < 0.05).In patients with more than 6 months of continuous BP treatment,the mean time to the first SRE was significantly longer than that in patients with less than 6 months of continuous BP treatment(7.2 vs.3.4 months,P < 0.05).In addition,12.2%of the physicians were not aware of the efficacy of BP in preventing and delaying *** half(52.3%) of the physicians agreed that the BP treatment should p

关键词： Bisphosphonates, Bone metastases, Skeleton-related events, Chinese cancer patients

Surufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: a phase Ib/Ⅱ trial

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2024年第10期9卷 4700-4707页

作者： Yaxiong Zhang Yan Huang Yunpeng Yang Yuanyuan Zhao Ting Zhou Gang Chen Shen Zhao Huaqiang Zhou Yuxiang Ma shaodong hong hongyun Zhao Li Zhang Wenfeng Fang Department of Medical Oncology State Key Laboratory of Oncology in South ChinaGuangdong Provincial Clinical Research Center for CancerCollaborative Innovation Center for Cancer MedicineSun Yat-sen University Cancer CenterGuangzhouChina Department of Clinical Research State Key Laboratory of Oncology in South ChinaGuangdong Provincial Clinical Research Center for CancerCollaborative Innovation Center for Cancer MedicineSun Yat-sen University Cancer CenterGuangzhouChina

There is still room for improvement in first-line treatment of advanced small cell lung cancer(SCLC).This trial firstly investigated efficacy and safety of antiangiogenic therapy(surufatinib)(200 mg,qd,po)plus anti-PD-1 treatment(toripalimab)(240 mg,d1,ivdrip)combined with etoposide(100 mg/m²,d1-d3,iv,drip)and cisplatin(25 mg/m²,d1-d3,ivdrip)for advanced SCLC as first-line treatment,which has been registered on *** under the identifier *** four-drug regimen was conducted q3w for 4 cycles with maintenance therapy of surufatinib and *** primary endpoint was progression-free survival(PFS).The secondary end points included objective response rate(ORR),disease control rate(DCR),overall survival(OS)and *** of the 38 patients were enrolled for safety analysis,while only 35 patients were enrolled for efficacy analysis since loss of efficacy evaluation in 3 cases after *** a median follow-up of 21.3 months,the ORR was 97.1%(34/35),and the DCR and the tumor shrinkage rate were both 100%(35/35).The median PFS was 6.9 months(95%CI:4.6 m–9.2 m)and the median OS was 21.1 months(95%CI:12.1 m–30.1 m).The 12-month,18-month,and 24-month OS rates were 66.94%,51.39%and 38.54%.The occurrence rate of grade≥3 treatment-emergent adverse events(TEAEs)was 63.2%(24/38),including neutrophil count decreased(31.6%,12/38),white blood cell count decreased(23.7%,9/38)and platelet count decreased(10.5%,4/38).No unexpected adverse events *** novel four-drug regimen(surufatinib,toripalimab,etoposide plus cisplatin)revealed impressive therapeutic efficacy and tolerable toxicities.

关键词： cisplatin patients etoposide

Preferable background filtering for next-generation sequencing analysis in non-small cell lung cancer:pericarcinomatous tissues or peripheral blood lymphocytes?

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Communications 2019年第1期39卷 314-317页

作者： Yaxiong Zhang Lianpeng Chang Wenfeng Fang Yunpeng Yang Lanjun Zhang shaodong hong Huaqiang Zhou Yanfang Guan Xin Yi Li Zhang State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer MedicineSun Yat-sen University Cancer CenterGuangzhou 510060GuangdongP.R.China Department of Medical Oncology Sun Yat-sen University Cancer Center651 Dongfeng Road EastGuangzhou 510060GuangdongP.R.China Geneplus-Beijing Institute Beijing 100000P.R.China Department of Thoracic Surgery Sun Yat-sen University Cancer CenterGuangzhou 510060GuangdongP.R.China

Dear editor,Lung cancer is the leading cause of cancer-related death worldwide,with the predominant pathological type being non-small cell lung cancer(NSCLC)[1,2].Next-gener-ation sequencing(NGS)analysis is increasingly used to help clinicians select appropriate target therapies,such as epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs)for EGFR-mutant patients[3].Both pericarcinomatous tissues and peripheral blood lymphocytes are widely used as normal control for NGS ***,whether pericarcinomatous tissue is suitable for background filtering in mutation analysis remains *** to the whole-genome sequencing data from The Cancer Genome Atlas(TCGA)database,there were some genomic variations in peri-carcinomatous tissue from NSCLC patients,but no driver gene mutation was detected[4,5].Therefore,deep sequencing of pericarcinomatous and tumor tissues is necessary to confirm whether pericarcinomatous tissue harbors low-frequency mutations.

关键词： lymphocytes lung filtering

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

肺癌靶向治疗新进展及展望

中国癌症杂志 2020年第10期30卷 733-743页

作者：洪少东张力中山大学肿瘤防治中心内科广东广州510060

近年来,靶向药物治疗已全面改变了肺癌的诊疗模式,并显著地改善了肺癌患者的生存期和生活质量。药物的更新迭代、靶向治疗模式的优化、耐药机制的探索、新靶点新药物的研发,不断地丰富肺癌靶向治疗的内容。针对驱动基因阳性肺癌的靶向... 详细信息

近年来,靶向药物治疗已全面改变了肺癌的诊疗模式,并显著地改善了肺癌患者的生存期和生活质量。药物的更新迭代、靶向治疗模式的优化、耐药机制的探索、新靶点新药物的研发,不断地丰富肺癌靶向治疗的内容。针对驱动基因阳性肺癌的靶向治疗最新进展和未来方向进行综述。

关键词：肺癌驱动基因靶向治疗耐药

比索洛尔对高龄慢性阻塞性肺疾病合并慢性心力衰竭的临床分析

在线全文

学校读者我要写书评

暂无评论

中国医药科学 2016年第11期6卷 94-96页

作者：洪少东广州市黄埔区中医医院广东广州510700

目的分析比索洛尔对于治疗高龄慢性阻塞性肺疾病合并慢性心力衰竭的临床疗效。方法选择我院86例COPD合并CHF患者作为观察对象,就诊时间为2014年1月-2015年4月,经伦理委员会通过,随机将其分成两组,对照组采用常规治疗,实验组在对照组基... 详细信息

目的分析比索洛尔对于治疗高龄慢性阻塞性肺疾病合并慢性心力衰竭的临床疗效。方法选择我院86例COPD合并CHF患者作为观察对象,就诊时间为2014年1月-2015年4月,经伦理委员会通过,随机将其分成两组,对照组采用常规治疗,实验组在对照组基础上加用比索洛尔进行治疗,观察两组高龄慢性阻塞性肺疾病合并慢性心力衰竭患者治疗半年后的临床效果。结果两组高龄慢性阻塞性肺疾病合并慢性心力衰竭患者治疗后左心室舒张末期内径、左心室射血分数、B型利钠肽前体、第一秒用力呼气量占预计值百分比等指标有统计学意义（P〈0.05）;不良反应发生率相比较,差异无统计学意义（P〉0.05）。结论针对高龄慢性阻塞性肺疾病合并慢性心力衰竭患者采用比索洛尔治疗的临床疗效显著,安全性较高。

关键词：比索洛尔高龄慢性阻塞性肺疾病慢性心力衰竭

基于改进人工势场法的山区公路自动驾驶车辆路径规划研究

在线全文

学校读者我要写书评

暂无评论

重庆理工大学学报（自然科学） 2020年第10期34卷 42-49页

作者：洪少东金志扬刘进一付丽荣邱娜黄武海南大学机电工程学院海南海口570100

针对目前的人工势场法应用于山区公路环境中的局限性,如主车与目标点的空间距离小于实际行驶距离而导致局部最小值的出现、障碍车辆斥力作用域不能随道路曲率的改变而变化导致干扰相邻车道中主车正常的行驶轨迹、双向车道中主车借道避... 详细信息

针对目前的人工势场法应用于山区公路环境中的局限性,如主车与目标点的空间距离小于实际行驶距离而导致局部最小值的出现、障碍车辆斥力作用域不能随道路曲率的改变而变化导致干扰相邻车道中主车正常的行驶轨迹、双向车道中主车借道避障行为发生后不能及时返回原车道而保持逆行等问题,基于人工势场法原理,建立了改进的自动驾驶车辆人工势场模型路径规划,提出了分段引力势场模型和障碍物随动斥力势场模型,同时引入车道边界梯度斥力势场模型,在结构化山区道路环境中进行避障路径规划。Matlab软件仿真结果表明:在双向行驶车道工况下,主车借道避开障碍物,驶离障碍物斥力作用域后将及时回到原车道,避免长时间逆向行驶;在平曲线车道工况下,主车将保持当前车道正常行驶,不会受到相邻车道正常行驶的车辆干扰主车的行驶轨迹;模拟结果中并未出现局部最小值,改进的人工势场模型能够规划出符合汽车实际行驶过程中的安全避障路径。

关键词：自动驾驶车辆路径规划山区公路改进人工势场法

中药离子导入联合骨刺贴局部敷贴治疗骨质增生症54例临床观察

在线全文

学校读者我要写书评

暂无评论

中医杂志 2011年第18期52卷 1581-1583页

作者：郝建军王翰屏洪少东李皓徐丽红陈伟文暨南大学医学院附属黄埔中医院

目的观察中药离子导入联合骨刺贴治疗骨质增生症的临床疗效和安全性。方法选择54例骨质增生症患者,采用中药离子导入联合骨刺贴治疗,每日1次,10次为1个疗程,休息1周后继续下一个疗程,共3个疗程。于治疗后1、2、3个月观察疗效,并于治疗... 详细信息

目的观察中药离子导入联合骨刺贴治疗骨质增生症的临床疗效和安全性。方法选择54例骨质增生症患者,采用中药离子导入联合骨刺贴治疗,每日1次,10次为1个疗程,休息1周后继续下一个疗程,共3个疗程。于治疗后1、2、3个月观察疗效,并于治疗前后不同时间进行临床症状积分评定。结果治疗2、3个月后临床显效率、总有效率均优于治疗1个月后(P<0.01);与治疗前比较,治疗后1、2、3个月患者症状体征总分的的均数、标准差、最小值及中位数均有统计学差异(P<0.01)。结论中药离子导入加骨刺贴局部敷贴在改善骨质增生症患者疼痛、肿胀、功能恢复程度等方面疗效确切,且安全性高。

关键词：骨质增生症中药离子导入骨刺贴

A Novel Parallel Scheme for Fast Similarity Search in Large Time Series

在线全文

学校读者我要写书评

暂无评论

China Communications 2015年第2期12卷 129-140页

作者： YIN hong YANG Shuqiang MA shaodong LIU Fei CHEN Zhikun College of Computer National University of Defense Technology Xiangyang School for NCOs School of Engineering The University of HullCottinghamRoad

The similarity search is one of the fundamental components in time series data mining,***,classification,association rules *** methods have been proposed to measure the similarity between time series,including Euclidean distance,Manhattan distance,and dynamic time warping(DTW).In contrast,DTW has been suggested to allow more robust similarity measure and be able to find the optimal alignment in time ***,due to its quadratic time and space complexity,DTW is not suitable for large time series *** improving algorithms have been proposed for DTW search in large databases,such as approximate search or exact indexed *** the previous modified algorithm,this paper presents a novel parallel scheme for fast similarity search based on DTW,which is called MRDTW(MapRedcuebased DTW).The experimental results show that our approach not only retained the original accuracy as DTW,but also greatly improved the efficiency of similarity measure in large time series.

关键词： similarity DTW warping path time series MapReduce parallelization cluster